Skip Nav Destination
Issues
1 November 2021
-
Cover Image
Cover Image
Vimseltinib is a colony stimulating factor 1 receptor (CSF1R) inhibitor that acts to block both autocrine signaling in tenosynovial giant cell tumor (TGCT) as well as paracrine signaling to inflammatory cells such as macrophages and osteoclasts. Vimseltinib was able to inhibit tumor growth in preclinical models and reduced biomarkers in three initial patients. Read the full study on page 2098. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Editorial
MCT First Disclosures
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D. Smith; Michael D. Kaufman; Scott C. Wise; Yu Mi Ahn; Timothy M. Caldwell; Cynthia B. Leary; Wei-Ping Lu; Gege Tan; Lakshminarayana Vogeti; Subha Vogeti; Breelyn A. Wilky; Lara E. Davis; Maitreyi Sharma; Rodrigo Ruiz-Soto; Daniel L. Flynn
A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer
Jiaojiao Deng; Sophia B. Chernikova; Yuelong Wang; Mirna L. Rodriguez; Stephanie J. Andersen; Maxine C. Umeh-Garcia; Bryanna O. Godfrey; Saman S. Ahmadian; Wolf-Nicolas Fischer; Kerry J. Koller; Bernd Jandeleit; Gordon M. Ringold; Melanie Hayden Gephart
Review
Small Molecule Therapeutics
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non–Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts
Andrew M. Baschnagel; Jacob H. Elnaggar; Haley J. VanBeek; Ashley C. Kromke; Justin H. Skiba; Saakshi Kaushik; Lindsey Abel; Paul A. Clark; Colin A. Longhurst; Kwangok P. Nickel; Ticiana A. Leal; Shuang G. Zhao; Randall J. Kimple
CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition
Mitchell G. Lawrence; Laura H. Porter; Nicholas Choo; David Pook; Jeremy P. Grummet; Carmel J. Pezaro; Shahneen Sandhu; Susanne Ramm; Jennii Luu; Andrew Bakshi; David L. Goode; Elaine Sanij; Richard B. Pearson; Ross D. Hannan; Kaylene J. Simpson; Renea A. Taylor; Gail P. Risbridger; Luc Furic
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Jessica Gartrell; Marcia Mellado-Largarde; Michael R. Clay; Armita Bahrami; Natasha A. Sahr; April Sykes; Kaley Blankenship; Lauren Hoffmann; Jia Xie; Hyekyung P. Cho; Nathaniel Twarog; Michele Connelly; Koon-Kiu Yan; Jiyang Yu; Shaina N. Porter; Shondra M. Pruett-Miller; Geoffrey Neale; Christopher L. Tinkle; Sara M. Federico; Elizabeth A. Stewart; Anang A. Shelat
The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Christopher W. Schultz; Grace A. McCarthy; Teena Nerwal; Avinoam Nevler; James B. DuHadaway; Matthew D. McCoy; Wei Jiang; Samantha Z. Brown; Austin Goetz; Aditi Jain; Valerie S. Calvert; Vikalp Vishwakarma; Dezhen Wang; Ranjan Preet; Joel Cassel; Ross Summer; Hoora Shaghaghi; Yves Pommier; Simone A. Baechler; Michael J. Pishvaian; Talia Golan; Charles J. Yeo; Emanuel F. Petricoin; George C. Prendergast; Joseph Salvino; Pankaj K. Singh; Dan A. Dixon; Jonathan R. Brody
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Paul Rossman; Tanja S. Zabka; Audrey Ruple; Dietrich Tuerck; José A. Ramos-Vara; Liling Liu; Rodrigo Mohallem; Mark Merchant; Jackeline Franco; Christopher M. Fulkerson; Ketaki P. Bhide; Matthew Breen; Uma K. Aryal; Elaine Murray; Noel Dybdal; Sagar M. Utturkar; Lindsey M. Fourez; Alexander W. Enstrom; Deepika Dhawan; Deborah W. Knapp
Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
Megan E. Zavorka Thomas; Xiyuan Lu; Zahra Talebi; Jae Yoon Jeon; Daelynn R. Buelow; Alice A. Gibson; Muhammad Erfan Uddin; Lindsey T. Brinton; Julie Nguyen; Meghan Collins; Alessia Lodi; Shannon R. Sweeney; Moray J. Campbell; Douglas H. Sweet; Alex Sparreboom; Rosa Lapalombella; Stefano Tiziani; Sharyn D. Baker
Large Molecule Therapeutics
NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both In Vitro and In Vivo
Yijun Cai; Jeremy P.H. Chow; Yu-On Leung; Xiaoxu Lu; Chak-Ho Yuen; Wing Lun Lee; Ka-Chun Chau; Liz L. Yang; Raymond M.H. Wong; Justin Y.T. Lam; Daniel T.L. Chow; Steven H.K. Chung; Sui-Yi Kwok; Yun-chung Leung
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
Samuel J. Klempner; Johanna C. Bendell; Victoria Meucci Villaflor; Laura LaNiel Tenner; Stacey M. Stein; James B. Rottman; Girish S. Naik; Cynthia A. Sirard; Michael H. Kagey; Marya F. Chaney; John H. Strickler
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
Melanie Wurm; Otmar Schaaf; Katharina Reutner; Rajkumar Ganesan; Sven Mostböck; Christina Pelster; Jark Böttcher; Bruna de Andrade Pereira; Christina Taubert; Isabella Alt; Garazi Serna; Aurelie Auguste; Kai B. Stadermann; Denis Delic; Fei Han; Jaume Capdevila; Paolo G. Nuciforo; Rachel Kroe-Barrett; Paul J. Adam; Anne B. Vogt; Irmgard Hofmann
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible
Taylor J. Jensen; Aaron M. Goodman; Christopher K. Ellison; Kimberly A. Holden; Shumei Kato; Lisa Kim; Gregory A. Daniels; Kerry Fitzgerald; Erin McCarthy; Prachi Nakashe; Amin R. Mazloom; Eyad Almasri; Graham McLennan; Daniel S. Grosu; Marcia Eisenberg; Razelle Kurzrock
Targeting Drug Resistance
Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Austin R. Dosch; Samara Singh; Xizi Dai; Siddharth Mehra; Iago De Castro Silva; Anna Bianchi; Supriya Srinivasan; Zhen Gao; Yuguang Ban; Xi Chen; Sulagna Banerjee; Nagaraj S. Nagathihalli; Jashodeep Datta; Nipun B. Merchant
Models and Technologies
Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non–Small Cell Lung Cancer and Triple-Negative Breast Cancer
Alison R. Mercer-Smith; Wulin Jiang; Juli R. Bago; Alain Valdivia; Morrent Thang; Alex S. Woodell; Stephanie A. Montgomery; Kevin T. Sheets; Carey K. Anders; Shawn D. Hingtgen
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds